Royal Bank Of Canada Mi Nk Therapeutics, Inc. Transaction History
Royal Bank Of Canada
- $425 Billion
- Q2 2024
A detailed history of Royal Bank Of Canada transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 160 shares of INKT stock, worth $116. This represents 0.0% of its overall portfolio holdings.
Number of Shares
160
Previous 124
29.03%
Holding current value
$116
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding INKT
# of Institutions
34Shares Held
912KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$170,9520.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$121,6660.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny128KShares$93,3230.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.3KShares$70,3330.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$63,6530.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $24.7M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...